{"id":"kogenate-bay14-2222","safety":{"commonSideEffects":[{"rate":null,"effect":"Inhibitor development (factor VIII antibodies)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Factor VIII is a critical cofactor in the intrinsic coagulation cascade that works with von Willebrand factor to activate factor X. In hemophilia A, factor VIII is deficient or non-functional, leading to impaired thrombin generation and bleeding. Kogenate provides exogenous factor VIII to restore normal coagulation and prevent or treat bleeding episodes.","oneSentence":"Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:19.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A (congenital factor VIII deficiency) — prevention and treatment of bleeding episodes"},{"name":"Perioperative management in hemophilia A patients"}]},"trialDetails":[{"nctId":"NCT02581969","phase":"","title":"Extension at 10 Years of the: \"Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.\"","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-04-14","conditions":"Hemophilia A","enrollment":43},{"nctId":"NCT01817868","phase":"","title":"Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-01-04","conditions":"Hemophilia","enrollment":73},{"nctId":"NCT02396862","phase":"","title":"Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-12-09","conditions":"Hemophilia A","enrollment":272},{"nctId":"NCT01184820","phase":"PHASE1","title":"Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-10-13","conditions":"Hemophilia A","enrollment":14},{"nctId":"NCT01029340","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12","conditions":"Blood Coagulation Disorders, Hemophilia A","enrollment":74},{"nctId":"NCT01436825","phase":"","title":"Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Haemophilia A","enrollment":69},{"nctId":"NCT00632814","phase":"PHASE4","title":"Russian Kogenate Pediatric Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Hemophilia A","enrollment":32},{"nctId":"NCT01810666","phase":"PHASE4","title":"Prophylaxis Versus on Demand Treatment for Children With Hemophilia A","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-03","conditions":"Hemophilia A","enrollment":30},{"nctId":"NCT00922597","phase":"","title":"Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08","conditions":"Hemophilia A","enrollment":26},{"nctId":"NCT00969319","phase":"","title":"Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-09","conditions":"Blood Coagulation Disorders, Hemophilia A","enrollment":105},{"nctId":"NCT00621673","phase":"PHASE4","title":"Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A","status":"TERMINATED","sponsor":"Bayer","startDate":"2006-05","conditions":"Hemophilia A","enrollment":1},{"nctId":"NCT00629837","phase":"PHASE1","title":"Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-09","conditions":"Hemophilia A","enrollment":27},{"nctId":"NCT00623480","phase":"PHASE3","title":"Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-03","conditions":"Hemophilia A","enrollment":84},{"nctId":"NCT00586521","phase":"PHASE4","title":"BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Hematologic Disease, Hemophilia A","enrollment":20},{"nctId":"NCT00782470","phase":"","title":"Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Hematologic Disease, Blood Coagulation Disorders","enrollment":38},{"nctId":"NCT01386268","phase":"","title":"Kogenate FS Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06","conditions":"Hemophilia A","enrollment":64},{"nctId":"NCT00874926","phase":"","title":"EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06","conditions":"Hemophilia A","enrollment":405},{"nctId":"NCT01653639","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-07","conditions":"Hemophilia A","enrollment":18},{"nctId":"NCT00623727","phase":"PHASE2","title":"BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A","status":"TERMINATED","sponsor":"Bayer","startDate":"2008-06","conditions":"Hemophilia A","enrollment":143},{"nctId":"NCT00932555","phase":"","title":"EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04","conditions":"Hemophilia A","enrollment":82},{"nctId":"NCT01159587","phase":"","title":"Prophylaxis Versus On-demand Therapy Through Economic Report","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Hemophilia A","enrollment":58},{"nctId":"NCT00606060","phase":"PHASE3","title":"BAY14-2222 Continuous Infusion in Surgeries","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Hemophilia","enrollment":15},{"nctId":"NCT00864552","phase":"","title":"International PMS Study - KOGENATE Bayer","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Hemophilia A","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Kogenate (BAY14-2222)","genericName":"Kogenate (BAY14-2222)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kogenate is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients. Used for Hemophilia A (congenital factor VIII deficiency) — prevention and treatment of bleeding episodes, Perioperative management in hemophilia A patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}